Connection
Virginia Borges to Estrogen Receptor Antagonists
This is a "connection" page, showing publications Virginia Borges has written about Estrogen Receptor Antagonists.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.242 |
|
|
|
-
Hamilton EP, Patel MR, Borges VF, Meisel JL, Okera M, Alemany CA, Pluard TJ, Wesolowski R, Sabanathan D, Miller KD, Conlin AK, McCarthy N, Shaw M, Tonda M, Shilkrut M, Lin NU. Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2-?advanced or metastatic breast cancer: phase 1/2 study results. Breast Cancer Res. 2025 Jul 01; 27(1):119.
Score: 0.242